Ageless Pep Academy Clinical Education · Licensed Prescribers

PMID-38851203 – NETTER-2 Lu-177-DOTATATE First-Line in GEP-NETs

PMID-38851203 – NETTER-2 Lu-177-DOTATATE First-Line in GEP-NETs

Singh S, Carnaghi C, Engstrom PF, et al. [177Lu]Lu-DOTA-[Tyr3]-octreotate plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10444):2807-2817.

Quick Reference

Property Value
PMID 38851203
DOI 10.1016/S0140-6736(24)00701-3
Year 2024
Journal The Lancet
Study Type RCT
Evidence Level I
Sample 222 patients with newly diagnosed grade 2-3 GEP-NETs
Peptide(s) Studied Lutetium-177-DOTATATE, Octreotide

Key Findings

  • Median PFS was 22.8 months with 177Lu-DOTATATE + octreotide LAR vs 8.5 months with high-dose octreotide LAR alone (HR 0.276; p < 0.0001)
  • First-line PRRT reduced risk of progression or death by 72% compared to somatostatin analog monotherapy
  • Objective response rate was significantly higher in the PRRT arm
  • Quality of life was maintained in both groups; no significant detriment from PRRT
  • Safety profile consistent with NETTER-1; grade 3-4 lymphopenia was the most common hematologic toxicity
  • This trial extended PRRT evidence to higher-grade (G2-G3) and treatment-naive patients — populations not studied in NETTER-1

Study Design

International, open-label, randomized (2:1), Phase 3 trial (NETTER-2; NCT03972488) across 45 centers in 9 countries. Newly diagnosed patients with advanced, well-differentiated, SSTR-positive grade 2-3 GEP-NETs were randomized to 177Lu-DOTATATE (4 cycles of 7.4 GBq IV every 8 weeks) plus octreotide LAR 30 mg, or high-dose octreotide LAR 60 mg every 4 weeks. Primary endpoint: PFS by blinded independent central review.

Limitations

  • Open-label design (blinding not feasible for radioligand therapy)
  • Overall survival data immature at time of publication
  • Limited to grade 2-3 tumors; may not be generalizable to grade 1 (indolent) NETs
  • No comparison with other active systemic therapies (e.g., everolimus, temozolomide)

Clinical Relevance

NETTER-2 is practice-changing: it establishes 177Lu-DOTATATE as a potential first-line therapy for higher-grade GEP-NETs, expanding its role beyond the second-line setting demonstrated in NETTER-1. The 14-month PFS improvement and 72% risk reduction position PRRT as the most effective first-line systemic therapy for SSTR-positive grade 2-3 GEP-NETs. This will likely shift treatment algorithms to earlier use of PRRT in patients with aggressive disease.

Related

#research #RCT #lutetium-177-DOTATATE #evidence-level-I